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ABSTRACT
Background
In the Strategies for Management of Anti-Retroviral Therapy trial, all-cause mortality was
higher for participants randomized to intermittent, CD4-guided antiretroviral treatment (ART)
(drug conservation [DC]) than continuous ART (viral suppression [VS]).
We hypothesized that increased HIV-RNA levels following ART interruption induced
activation of tissue factor pathways, thrombosis, and fibrinolysis.
Methods and Findings
Stored samples were used to measure six biomarkers: high sensitivity C-reactive protein
(hsCRP), interleukin-6 (IL-6), amyloid A, amyloid P, D-dimer, and prothrombin fragment 1þ2.
Two studies were conducted: (1) a nested case–control study for studying biomarker
associations with mortality, and (2) a study to compare DC and VS participants for biomarker
changes. For (1), markers were determined at study entry and before death (latest level) for 85
deaths and for two controls (n¼170) matched on country, age, sex, and date of randomization.
Odds ratios (ORs) were estimated with logistic regression. For each biomarker, each of the three
upper quartiles was compared to the lowest quartile. For (2), the biomarkers were assessed for
249 DC and 250 VS participants at study entry and 1 mo following randomization. Higher levels
of hsCRP, IL-6, and D-dimer at study entry were significantly associated with an increased risk of
all-cause mortality. Unadjusted ORs (highest versus lowest quartile) were 2.0 (95% confidence
interval [CI], 1.0–4.1; p¼0.05), 8.3 (95% CI, 3.3–20.8; p , 0.0001), and 12.4 (95% CI, 4.2–37.0; p ,
0.0001), respectively. Associations were significant after adjustment, when the DC and VS
groups were analyzed separately, and when latest levels were assessed. IL-6 and D-dimer
increased at 1 mo by 30% and 16% in the DC group and by 0% and 5% in the VS group (p ,
0.0001 for treatment difference for both biomarkers); increases in the DC group were related to
HIV-RNA levels at 1 mo (p , 0.0001). In an expanded case–control analysis (four controls per
case), the OR (DC/VS) for mortality was reduced from 1.8 (95% CI, 1.1–3.1; p¼0.02) to 1.5 (95%
CI, 0.8–2.8) and 1.4 (95% CI, 0.8–2.5) after adjustment for latest levels of IL-6 and D-dimer,
respectively.
Conclusions
IL-6 and D-dimer were strongly related to all-cause mortality. Interrupting ART may further
increase the risk of death by raising IL-6 and D-dimer levels. Therapies that reduce the
inflammatory response to HIV and decrease IL-6 and D-dimer levels may warrant investigation.
Trial Registration: ClinicalTrials.gov (NCT00027352).
The Editors’ Summary of this article follows the references.
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The Strategies for Management of Anti-Retroviral Therapy
(SMART) trial compared episodic use of antiretroviral treat-
ment (ART) guided by CD4þ count with the current practice
of continuous ART. Risk of opportunistic disease (OD) or
death was more than twice as great for those in the episodic
compared to the continuous ART group (hazard ratio¼2.6; p
, 0.001). The episodic ART strategy was also associated with
an 84% (p ¼ 0.007) increased risk of all-cause mortality. Most
of the deaths that occurred were not attributable to AIDS-
deﬁning conditions [1].
Several studies have shown that HIV replication is an
important determinant of endothelial dysfunction [2–5]. As a
consequence of impaired endothelial function, HIV-infected
patients may be in a hypercoagulable state [6]. In cross-
sectional studies, higher levels of IL-6, an inﬂammatory
cytokine, have been found for HIV-infected compared to
uninfected individuals [7,8]. IL-6 has also been shown to be
correlated with HIV-RNA levels among patients with
advanced HIV [9]. C-reactive protein, a proinﬂammatory
marker, increases over time for patients with HIV, and
individuals who progress to AIDS have greater increases [10].
We hypothesized that increased HIV-RNA levels following
ART interruption induced activation of tissue factor path-
ways, thrombosis, and ﬁbrinolysis, and that these inﬂamma-
tory changes were associated with an increased risk of all-
cause mortality.
Prior studies of inﬂammatory and coagulation markers in
HIV-infected patients have not compared those using ART
and not using ART in a randomized trial, thereby controlling
known and unknown confounding variables. To our knowl-
edge, this is the ﬁrst planned investigation of inﬂammatory
and coagulation markers with all-cause mortality in HIV-
infected patients.
Methods
The methods and results of the SMART trial have been
published [1].
Study Population
5,472 HIV-infected participants were enrolled at 318 sites
in 33 countries. Patients were eligible if they had a CD4þ
count over 350 cells/mm
3 and were willing to initiate, modify,
or stop ART as per study guidelines [1]. Participants were
asked to consent to storing blood for future research, and
only samples from consenting participants were used. The
SMART study, including the consent for stored specimens,
was approved by the institutional review board at each site
and at the University of Minnesota, which served as the
Statistical and Data Management Center. The institutional
review board at the University of Minnesota also approved
plans for analysis of stored specimens for consenting
participants.
Study Treatments
In SMART, patients were randomized to one of two ART
strategies. The viral suppression (VS) strategy aimed to
maximally suppress viral replication by continuous use of
ART. The drug conservation (DC) strategy entailed inter-
mittent use of ART for periods deﬁned by CD4þ count
thresholds. Use of ART was stopped (or deferred) until CD4þ
count dropped to less than 250 cells/mm
3, at which time ART
was to be (re-)initiated and continued until the CD4þ count
rose above 350 cells/mm
3. Upon conﬁrmation that the CD4þ
count was over 350 cells/mm
3, ART was to be stopped and
resumed again when CD4þ count was below 250 cells/mm
3.
During periods of ART use, the goal was to achieve maximal
viral suppression.
Clinical Outcomes
Underlying cause of death was classiﬁed using the CoDe
system by an Endpoint Review Committee blinded to treat-
ment group [11]. As previously reported, only four of 55
deaths in the DC group and three of 30 deaths in the VS
group were attributable to opportunistic diseases (Table S1)
[1]. Because no single cause of death dominated the treatment
difference, we focus on all-cause mortality in this report.
Biomarker Substudy
In SMART, follow-up study visits occurred at month 1,
month 2, then every 2 mo for the ﬁrst year, and every 4 mo
thereafter. Of the 5,472 participants in SMART, 1,415 in the
United States were asked to consent prior to randomization
to have plasma stored at baseline (study entry) and at every
follow-up visit beginning with the 1-mo visit; 1,361 of these
participants consented. For the remaining 4,057 participants,
consent was requested at the time of randomization for
storing blood at either 4- or 12-mo intervals; 3,800 of these
participants consented. Plasma specimens were collected
using EDTA (lavender top) blood collection tubes and were
shipped frozen to a central repository.
Only specimens obtained prior to 11 January 2006, were
used for the analyses described in this paper. As previously
reported, on that date investigators and ART-experienced
participants were notiﬁed of a safety risk in the DC group,
enrollment was stopped, and participants in the DC group
were advised to restart ART [1].
Four inﬂammatory markers, high sensitivity C-reactive
protein (hsCRP), IL-6, amyloid A, and amyloid P, and two
coagulation markers, D-dimer and prothrombin fragment
1þ2 (F1.2), were measured by the Laboratory for Clinical
Biochemistry Research at the University of Vermont for cases
and controls and for a random sample of participants in each
treatment group. Biomarkers for the random sample and the
case–control study were analyzed in the same batches blinded
to treatment group (DC or VS) and case–control status. These
six biomarkers were prospectively chosen because they have
high laboratory and biological reproducibility [12] and have
been associated with all-cause mortality and cardiovascular
disease (CVD) in studies of the general population [13–25].
These were the only six biomarkers included in this
investigation.
Nested case–control study. Plasma samples collected at
baseline and during follow-up were identiﬁed for all who died
(85 participants) prior to 11 January 2006, and for two
matched controls for each death (170 patients) (Figure 1).
Matching was on country, age (6 5 y), sex, and approximate
date of randomization (6 3 mo). Age was chosen as a
matching variable because of its known association with
mortality; sex was chosen for consistency with other case–
control studies being done with SMART participants, e.g.,
with CVD cases, in which sex is an established risk factor;
country (site within country where possible) was chosen as a
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treatment patterns, demographics, and other factors that
could vary by site or location; and date of randomization was
chosen as a matching variable to ensure that latest levels for
cases and controls were measured at approximately the same
time following randomization. These matching factors were
also chosen because they were clearly not on the causal
pathway between the biomarkers and mortality. Controlling
for other potential confounding factors was by regression
adjustment.
The single follow-up specimen selected for each partic-
ipant was from the visit before death (latest level). Specimens
from the same follow-up visit were used for the matched
controls. Follow-up specimens were available for 74 deaths
and 141 controls. The median time between measurement of
follow-up biomarkers and death was 69 d (25th and 75th
percentiles were 40 d and 149 d, respectively).
Nested case–control studies with the same matching
criteria were also carried out for all cases of AIDS and for
cases of CVD, renal disease, and liver disease. These studies
will be reported separately. In selected analyses, controls
from these studies were used to supplement the controls
chosen for deaths (Figure S1). Speciﬁcally, among the 561
controls chosen for deaths, AIDS, CVD, renal, and liver
events, four controls randomized at approximately the same
time as the death (6 3 mo) were chosen without replacement
for each death (340 total).
Random sample. Specimens collected at study entry and 1
mo after randomization were identiﬁed for a random sample
of 250 participants from each treatment group who reported
no history of CVD at entry (Figure 2). One participant in the
DC group who was chosen for analysis did not have an
adequate study entry specimen. Thus, analyses are based on
499 participants.
Statistical Methods
Summary statistics and illustrations appropriate for
matched case–control studies were used to summarize key
ﬁndings [26]. Conditional logistic regression analyses for
matched case–control studies were carried out to study the
associations of baseline and latest levels for each biomarker
with all-cause mortality. Separate analyses by quartile of each
biomarker (deﬁned using the random sample) were per-
formed and ORs for each of the three upper quartiles versus
the lowest quartile (reference group) are cited along with
95% conﬁdence intervals (CIs) and p-values. In addition to
models that categorized biomarkers according to quartiles,
models with log10 transformed biomarker levels were
considered, and estimated parameters were used to deter-
mine the increase in risk associated with a difference in the
biomarker corresponding to its interquartile range (IQR).
The IQR was determined from the random sample of 499
study participants. Separate models were ﬁt for each
biomarker. The following covariates assessed at study entry
were used for the adjusted analyses cited: age, self-reported
race (categorized for this analysis as black versus other), use of
ART and HIV-RNA level (no ART, versus ART and  400
copies/ml, versus ART and .400 copies/ml), CD4þ cell count,
smoking status, body mass index (BMI), prior CVD, diabetes,
use of blood pressure (BP) medication, use of lipid-lowering
medication, total/HDL cholesterol, co-infection with hepatitis
B or C, and treatment group.
For some biomarkers very large ORs for the associations
with mortality were observed. To investigate the possibility
that these large ORs were due to sparse data [27], the number
of covariates considered [28], or outliers, four sensitivity
analyses were performed: (1) conditional logistic models that
included only baseline covariates that were signiﬁcant at the
0.10 level in a multivariable analysis with mortality (age, prior
CVD, co-infection with hepatitis B or C, smoking, and
baseline CD4þ cell count); (2) unconditional logistic models;
(3) conditional logistic models that excluded outliers, i.e.,
levels below the lower fence, deﬁned as the lower quartile –
1.5 3 IQR or above the upper fence (upper quartile þ 1.5 3
IQR) [29]; and (4) conditional logistic models that used four
controls per case with controls only matched on date of
randomization (6 3 mo).
The associations between baseline biomarker levels and
mortality were considered for DC and VS participants
separately. To assess whether associations between biomarker
levels and mortality varied by treatment group, an interaction
term (product of log10 transformed biomarker and treatment
group) was included in the logistic models. Similar methods
were used for studying subgroups deﬁned by prior disease
history, co-infection with hepatitis, and baseline CD4þ cell
count.
For analyses of latest biomarker levels and mortality, log10
transformed levels were used, and the study entry level of the
biomarker that was the focus of the analysis was included as a
covariate with other previously cited covariates. To assess the
effects of biomarker differences between the DC and VS
groups on the DC/VS OR for mortality, conditional logistic
models that included the latest level of the biomarker as well
as the treatment indicator were considered. For these
analyses, deaths and the four controls matched on date of
randomization were used. This expanded case–control study
(four instead of two controls) was used because there was a
chance difference in the number of DC and VS controls with
latest biomarker levels in the case–control study with 1:2
matching. This resulted in an unadjusted DC versus VS
difference in mortality that was not as great as previously
reported [1]. Because the focus was on the risk of death in the
DC versus VS group, a comparison protected by random-
ization, matching was limited to date of randomization to
ensure latest biomarker levels were measured at approx-
imately the same time for each death and the four matched
controls.
The association between each biomarker and other
covariates at study entry was studied using linear regression
analysis. Biomarker changes after 1 mo were compared for
DC and VS participants using analysis of covariance. The
association of biomarker change (after log10 transformation)
and HIV-RNA change at 1 mo for DC participants with an
HIV-RNA level  400 copies/ml at study entry was studied
using linear regression analysis.
Statistical analyses were performed using SAS (Version 9.1)
[30]. All reported p-values are two-sided.
Results
Case–Control Sample: Baseline Biomarkers and All-Cause
Mortality
Most of the deaths (79 of 85) occurred in the US. Sites in
the US began enrollment 2 to 3 y before most sites in other
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participants. In univariate analyses, cases and controls
differed with respect to age (p ¼ 0.007), baseline CD4þ count
(p ¼ 0.03), co-infection with hepatitis B or C (p ¼ 0.0008),
smoking status (p ¼ 0.0001), diabetes (p ¼ 0.03), use of BP-
lowering treatment (p¼0.02), and prior CVD (p¼0.04) (Table
1). In multivariate analyses that included the baseline
covariates described in Methods for adjusted analyses, age
(p ¼ 0.02), smoking (p ¼ 0.01), prior CVD (p ¼ 0.04), co-
infection with hepatitis B or C (p ¼ 0.03), and baseline CD4þ
cell count (p ¼ 0.10) were associated (p ¼ 0.10 or lower) with
mortality.
With the exception of amyloid P, levels of the inﬂammatory
markers were higher in deaths than matched controls (Table
2, ‘‘study entry’’). Differences between deaths and controls for
IL-6 and D-dimer were highly signiﬁcant (p , 0.0001); hsCRP
was also signiﬁcantly higher among deaths than controls (p ¼
0.005).
Figures S2–S7 display biomarker levels for each triad
(death and two matched controls) ordered by the biomarker
level for the death. For IL-6 (Figure S5) and D-dimer (Figure
S6), and to a lesser extent hsCRP (Figure S2), there is a shift in
the distribution for deaths (red circles) compared to controls
(blue circles). For other biomarkers, control levels are lower
Figure 1. SMART Study Design and Flow Diagram for Case–Control Study
doi:10.1371/journal.pmed.0050203.g001
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levels (in part, a reﬂection of the regression to the mean
phenomenon).
For both IL-6 and D-dimer, the discordance of cases and
matched controls in the lower quartile (,25th percentile) and
upper quartile (.75th percentile) was striking. For D-dimer,
there were 23 controls with levels in the lowest quartile
(,0.18 lg/ml) that were matched with deaths that had levels in
the upper quartile. In contrast, there were only two controls
with D-dimer levels in the upper quartile matched with
deaths in the lowest quartile. For IL-6, there were 25 controls
with levels in the lowest quartile (,1.6 pg/ml) matched with
deaths that had levels in the upper quartile, and three
controls with IL-6 in the upper quartile matched with deaths
in the lowest quartile.
Strong risk gradients with mortality were evident for both
IL-6 and D-dimer (Table 3). For IL-6, unadjusted ORs (for
each of the three upper quartiles versus lowest) were 8.3 (95%
CI, 3.3–20.8), 3.2 (95% CI, 1.3–7.9), and 1.3 (95% CI, 0.5–3.6).
For D-dimer corresponding ORs were 12.4 (95% CI, 4.2–37.0),
4.0 (95% CI, 1.3–12.3), and 3.2 (95% CI, 1.1–9.0). In models
that considered these biomarkers as continuous variables
after log10 transformation, a difference corresponding to the
IQR was associated with an OR of 3.4 (95% CI, 2.2–5.4) for IL-
6 and 3.9 (95% CI, 2.3–6.6) for D-dimer. Covariate adjustment
tended to strengthen these associations (Table 3), and
sensitivity analyses yielded consistent ﬁndings (Table S2).
Similar analyses with the 1:4 matching yielded results with
reduced, but still very large, ORs for IL-6 and D-dimer (Table
S3). For example, unadjusted ORs (upper quartile versus
lowest) were 6.1 (95% CI, 2.7–13.6) and 6.6 (95% CI, 2.9–14.9)
for IL-6 and D-dimer, respectively.
Signiﬁcant associations between study entry levels of
hsCRP and amyloid P and mortality were also evident. Risk
of death increased with increasing levels of hsCRP but not as
strongly as for IL-6 and D-dimer. The unadjusted OR (upper
versus lower quartile of hsCRP) was 2.0 (95% CI, 1.0–4.1).
Higher levels of amyloid P were associated with a lower risk of
death in analyses based on the continuous biomarker level,
but no apparent trend by quartile was evident. This
association was only of borderline signiﬁcance after covariate
adjustment and may be due in part to outliers. After
excluding outliers (ten deaths and seven controls), the OR
associated with a one IQR higher level of amyloid P was 1.1
(95% CI, 0.7–1.7) (Table S2).
When IL-6 and D-dimer were considered together in the
same model they each remained signiﬁcantly associated with
all-cause mortality. Unadjusted ORs for the highest versus
lowest quartile were 4.7 (95% CI, 1.7–12.7; p ¼0.002) for IL-6
and 6.1 (95% CI, 2.0–18.6; p ¼ 0.001) for D-dimer. ORs for a
difference corresponding to the IQR were 2.7 (95% CI, 1.6–
4.4; p , 0.0001) for IL-6 and 2.6 (95% CI, 1.5–4.6; p ¼ 0.001)
for D-dimer.
In the analyses described above, the DC and VS groups
were combined. In separate analyses for each group (Table 4),
associations between biomarker levels at baseline and
Figure 2. SMART Study Design and Flow Diagram for Random Sample
doi:10.1371/journal.pmed.0050203.g002
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comparison to models that considered both treatment groups
combined). For DC participants, median levels (expressed as
deaths, controls) were 4.49, 1.78 lg/ml for hsCRP; 3.85, 2.24
pg/ml for IL-6; and 0.63, 0.22 lg/ml for D-dimer. For VS
participants, these median levels were 3.60, 3.07 lg/ml for
hsCRP; 3.78, 2.43 pg/ml for IL-6; and 0.37, 0.29 lg/ml for D-
dimer.
Likewise, associations were similar for those with prior
cancer, CVD, renal or liver disease (31% of deaths and 16% of
controls), and those with no history of these conditions (p ¼
0.33 for hsCRP, p ¼ 0.88 for IL-6, and p ¼ 0.74 for D-dimer
interactions); for those co-infected with hepatitis or not (p ¼
0.37 for hsCRP, p ¼ 0.41 for IL-6, and p ¼ 0.76 for D-dimer
interactions); and for those with a baseline CD4þcell less than
600 cells/mm
3 (approximate median) and 600 cells/mm
3 or
more(p¼0.85 for hsCRP, p¼0.21 for IL-6, and p¼0.41 for D-
dimer interactions).
Associations with hsCRP, Il-6, and D-dimer were also
similar for deaths in the ﬁrst year (38 deaths) and after the
ﬁrst year (47 deaths). During the ﬁrst year, the OR
corresponding to the IQR for hsCRP, IL-6, and D-dimer
were 1.5 (95% CI, 0.9–2.4; p ¼ 0.16), 2.5 (95% CI, 1.4–4.3; p ¼
0.002), and 3.9 (95% CI, 1.9–8.0; p ¼ 0.0003), respectively. For
Table 1. Characteristics of Deaths and Matched Controls at Study Entry
Category Subcategory Deaths (n ¼ 85) Controls (n ¼ 170) p-Value
a
Demographics Age (25
th,7 5
th %ile) 50 (42, 56) 48 (43, 55) 0.007
Sex (% female) 23.5 23.5 NA
Race (self-reported) White (%) 48.2 54.7 (ref.)
Black (%) 49.4 41.8 0.26
Other (%) 2.4 3.5 0.77
CD4þ (cells/mm
3) Nadir CD4þ (25
th,7 5
th %ile) 247 (152, 350) 243 (105, 370) 0.80
Baseline (25
th,7 5
th %ile) 545 (408, 693) 614 (477, 800) 0.03
Prior AIDS (%) — 31.8 26.5 0.36
United States site (%) — 92.9 92.9 NA
ART/HIV-RNA No ART (%) 22.3 15.9 (ref.)
ART and HIV-RNA  400 copies/ml (%) 51.8 62.9 0.13
ART and HIV-RNA .400 copies/ml (%) 25.9 21.2 0.71
Co-infection with hepatitis B/C (%) — 45.9 24.1 0.0008
Other risk factors Current smoker (%) 57.6 31.8 0.0001
Diabetes (%) 25.9 14.7 0.03
Blood pressure–lowering drugs (%) 38.8 25.3 0.02
Lipid-lowering drugs (%) 16.5 22.9 0.21
Prior CVD (%) 11.8 4.7 0.04
Total/HDL cholesterol (25th, 75th %ile) 4.5 (3.4, 6.2) 4.7 (3.7, 5.9) 0.32
BMI (kg/m
2) (25th, 75th %ile) 24.8 (21.6, 29.9) 25.6 (23.4, 29.4) 0.71
Treatment group (% DC) — 64.7 58.2 0.34
Controls were matched on age (6 5 y), country, sex, and date of randomization. Medians are cited for measured variables along with the 25th and 75th percentiles.
ap-Value obtained from univariate conditional logistic model.
doi:10.1371/journal.pmed.0050203.t001
Table 2. Study Entry and Latest Levels of Six Biomarkers for Deaths and Matched Controls
Sampling Point Biomarker Deaths, Median
(25th, 75th %ile)
Controls, Median
(25th, 75th %ile)
Difference (Case–Control)
after Log10 Transformation (SE)
p-Value
a
Study entry
b hsCRP (lg/ml) 4.26 (2.12, 7.49) 2.14 (0.84, 5.68) 0.21 (0.07) 0.005
Amyloid A (mg/l) 4.75 (2.80, 9.06) 3.65 (1.90, 8.08) 0.10 (0.06) 0.11
Amyloid P (lg/ml) 58.8 (43.1, 82.3) 67.8 (48.8, 94.1)  0.08 (0.03) 0.009
IL-6 (pg/ml) 3.80 (2.72, 7.20) 2.31 (1.51, 3.33) 0.29 (0.04) ,0.0001
D-dimer (lg/ml) 0.49 (0.27, 1.16) 0.26 (0.17, 0.45) 0.35 (0.06) ,0.0001
F1.2 (pmol/l) 344.0 (245.8, 565.8) 351.4 (255.5, 533.4) 0.01 (0.04) 0.81
Latest level
c hsCRP (lg/ml) 5.26 (2.19, 19.3) 2.00 (0.78, 4.80) 0.47 (0.09) ,0.0001
Amyloid A (mg/l) 6.88 (2.40, 16.7) 3.35 (2.00, 6.75) 0.28 (0.08) 0.002
Amyloid P (lg/ml) 57.7 (34.9, 78.5) 67.3 (49.6, 88.1)  0.09 (0.03) 0.009
IL-6 (pg/ml) 7.84 (3.08, 15.5) 2.72 (1.60, 4.39) 0.45 (0.06) ,0.0001
D-dimer (lg/ml) 0.70 (0.34, 1.64) 0.34 (0.22, 0.63) 0.39 (0.07) ,0.0001
F1.2 (pmol/l) 339.5 (260.6, 463.7) 321.1 (218.8, 507.4)  0.01 (0.04) 0.93
ap-Value obtained from a conditional logistic model with a single covariate corresponding to log10 transformed biomarker level.
b85 deaths and 170 controls (see Figure 1).
c74 deaths and 141 controls (see Figure 1).
SE, standard error.
doi:10.1371/journal.pmed.0050203.t002
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D-dimer were 1.9 (95% CI, 1.1–3.2; p¼0.01), 5.0 (95% CI, 2.4–
10.4; p , 0.0001), and 3.9 (95% CI, 1.8–8.4; p ¼ 0.0005).
Deaths due to substance abuse (eight deaths) or to
accidents, violence, or suicide (seven deaths) could attenuate
the associations between the biomarkers and mortality. Thus,
analyses were carried out excluding these 15 deaths.
Unadjusted ORs corresponding to a difference equal to the
IQR were 1.9 (95% CI, 1.2–2.8) for hsCRP, 3.7 (95% CI, 2.2–
6.3) for IL-6, and 4.0 (95% CI, 2.1–7.4) for D-dimer. Each of
these ORs is larger by a small amount compared to the
corresponding estimates in Table 3. Twenty-one deaths were
classiﬁed as CVD or were unwitnessed. Unadjusted ORs of
CVD or unwitnessed death corresponding to a difference
equal to the IQR were 2.3 (95% CI, 1.0–5.0; p ¼ 0.04) for
hsCRP, 3.2 (95% CI, 1.2–8.4; p ¼ 0.02) for IL-6, and 3.2 (95%
CI, 1.1–9.3; p ¼ 0.04) for D-dimer.
Case–Control Sample: Change in Biomarkers and All-
Cause Mortality
Table 2 (‘‘latest level’’) compares latest levels of each
biomarker for deaths and matched controls (Table S4 gives
similar results for the 1:4 matching). In these univariate
analyses, signiﬁcant differences were observed for all of the
biomarkers except F1.2. Deaths had higher latest levels than
controls, except amyloid P for which latest levels were lower
for deaths than controls. Findings were strongest for hsCRP,
IL-6, and D-dimer. Average differences between deaths and
controls were greater for latest levels than for study entry
levels (Table 2 ‘‘study entry’’ and Table S4).
Table 5 gives adjusted ORs for latest levels of each
biomarker. Adjusted ORs corresponding to a difference
equal to the IQR were 2.4 (95% CI, 1.4–4.2) for hsCRP, 2.0
(95% CI, 1.2–3.1) for IL-6, and 2.2 (95% CI, 1.1–4.1) for D-
dimer. These models also included study entry levels of each
biomarker. Study entry levels of IL-6 and D-dimer remained
signiﬁcantly associated with all-cause mortality after consid-
eration of latest levels (p¼0.0008 for IL-6 and p¼0.003 for D-
dimer). After considering latest level of hsCRP, the study
entry level was not signiﬁcant (p ¼ 0.07). In models that also
included latest levels of HIV-RNA and CD4þ cell count,
neither of which were signiﬁcantly associated with all-cause
mortality, these associations were diminished slightly but
remained signiﬁcant. For latest levels of hsCRP, IL-6, and D-
dimer, the ORs were 2.2 (p¼0.009), 1.7 (p¼0.04), and 2.0 (p¼
0.04).
Random Sample: Associations at Baseline
As previously reported, the majority of patients in SMART
were using ART at entry [1]. In the random sample, 74% were
Table 3. Risk of Death Associated with Biomarker Levels at Study Entry
Biomarker Type of
Analysis
,25
th
Percentile
(Reference)
25th–49th
Percentile
50th–74th
Percentile
 75
th
Percentile
OR associated with One
IQR Higher Biomarker Level
after Log10 Transformation
OR
(95% CI)
p-Value OR
(95% CI)
p-Value OR
(95% CI)
p-Value OR
(95% CI)
p-Value
hsCRP
(lg/ml)
No.
a 16/45 9/42 20/28 40/55
Univariate 1.0 (ref.) 0.6 (0.2–1.5) 0.29 2.0 (0.9–4.6) 0.09 2.0 (1.0–4.1) 0.05 1.7 (1.2–2.4) 0.005
Adjusted 1.0 (ref.) 0.7 (0.2–2.1) 0.50 2.5 (0.9–7.2) 0.08 3.1 (1.2–8.0) 0.02 2.3 (1.4–3.7) 0.001
Amyloid A
(mg/l)
No. 11/46 17/35 28/33 29/56
Univariate 1.0 (ref.) 2.0 (0.8–5.2) 0.13 3.4 (1.5–7.7) 0.005 2.2 (0.9–5.2) 0.07 1.3 (0.9–1.7) 0.11
Adjusted 1.0 (ref.) 3.4 (1.0–11.1) 0.04 3.5 (1.2–10.2) 0.02 3.1 (1.0–9.5) 0.05 1.3 (0.9–1.9) 0.12
Amyloid P
(lg/ml)
No. 25/44 20/25 16/43 24/56
Univariate 1.0 (ref.) 1.5 (0.7–3.1) 0.32 0.7 (0.3–1.4) 0.32 0.7 (0.4–1.5) 0.39 0.7 (0.6–0.9) 0.009
Adjusted 1.0 (ref.) 1.5 (0.6–4.0) 0.42 0.8 (0.3–2.0) 0.65 1.1 (0.4–3.0) 0.78 0.7 (0.5–1.0) 0.06
IL-6
(pg/ml)
No. 8/48 10/41 26/48 40/29
Univariate 1.0 (ref.) 1.3 (0.5–3.6) 0.62 3.2 (1.3–7.9) 0.01 8.3 (3.3–20.8) ,0.0001 3.4 (2.2–5.4) ,0.0001
Adjusted 1.0 (ref.) 1.0 (0.3–3.6) 0.98 4.5 (1.4–14.2) 0.01 12.4 (3.6–42.0) ,0.0001 4.1 (2.3–7.3) ,0.0001
D-dimer
(lg/ml)
No. 8/51 22/54 18/40 37/25
Univariate 1.0 (ref.) 3.2 (1.1–9.0) 0.03 4.0 (1.3–12.3) 0.02 12.4 (4.2–37.0) ,0.0001 3.9 (2.3–6.6) ,0.0001
Adjusted 1.0 (ref.) 8.3 (1.9–36.8) 0.005 12.6 (2.4–65.1) 0.003 41.2 (7.5–225.6) ,0.0001 5.3 (2.6–10.9) ,0.0001
F1.2
(pmol/l)
No. 17/29 21/43 15/43 31/53
Univariate 1.0 (ref.) 0.8 (0.4–1.9) 0.64 0.6 (0.3–1.5) 0.28 1.0 (0.5–2.1) 0.92 1.0 (0.8–1.4) 0.81
Adjusted 1.0 (ref.) 1.0 (0.4–2.9) 0.94 0.9 (0.3–2.6) 0.82 1.3 (0.5–3.4) 0.64 1.1 (0.7–1.6) 0.71
Odds ratios are derived from separate conditional logistic models for each biomarker (two unadjusted-univariate and two adjusted models for each biomarker, one with quartiles and one
with continuous level of biomarker after log10 transformation); adjusted models include age, race, use of ART and HIV-RNA level, CD4þcell count, smoking status, BMI, prior CVD, diabetes,
use of BP medication, use of lipid-lowering medication, total/HDL cholesterol, co-infection with hepatitis B or C, and treatment group. Percentile definitions are based on the random
sample of 499 participants (see Figure 2). Percentile cut-off points (IQR on log10 scale) are hsCRP: ,0.93, 0.93–2.29, 2.30–4.69,  4.70 (0.71); amyloid A: ,2.0, 2.0–3.4, 3.5–6.3,  6.4 (0.50);
amyloid P: ,49, 49–60, 61–80, 81 (0.22); IL-6: ,1.6, 1.6–2.3, 2.4–3.8,  3.9 (0.39); D-dimer: ,0.18, 0.18–0.33, 0.34–0.63,  0.64 (0.58); F1.2: ,225, 225–319, 320–464,  465 (0.32).
a No. is number of cases/controls
doi:10.1371/journal.pmed.0050203.t003
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level 400 copies/ml or lower. Approximately 6% of patients
had not previously used ART; the remainder of those not
using ART had discontinued it prior to enrolling in SMART.
In the random sample, treatment groups were well balanced
(Table 6).
Multiple regression analyses of each biomarker (after log10
transformation) on baseline covariates were performed. The
covariates used in the regression analyses were the same as
those used in the adjusted case–control analysis. An excep-
tion was history of CVD since no one in the random sample
had a history of CVD (Figure 2). D-dimer was signiﬁcantly
higher for those not on ART than for those on ART with an
HIV-RNA level 400 copies/ml or lower (0.15 on log10 scale; p¼
0.0007) and for those on ART with an HIV-RNA over 400
copies/ml (0.12; p ¼ 0.02). Other biomarkers did not vary
signiﬁcantly according to use of ART and HIV-RNA level at
study entry.
Smoking and co-infection with hepatitis B or C, which were
both signiﬁcantly related to mortality, were not signiﬁcantly
associated with either IL-6 (p¼0.19 for smoking and p¼0.16
for co-infection) or D-dimer (p ¼ 0.64 for smoking and p ¼
0.39 for co-infection) at baseline. Smoking was not signiﬁ-
cantly associated with any of the biomarkers. hsCRP was
lower by 0.217 lg/ml after log10 transformation (p ¼ 0.0001)
and amyloid P was lower by 0.068 (p ¼ 0.0005) for those who
were co-infected with hepatitis; co-infection was not asso-
ciated with the other biomarkers.
Signiﬁcant predictors of log10 IL-6 were age (0.069 higher
with each 10 y in age; p , 0.0001) and BMI (0.009 higher with
each kg/m
2 greater BMI; p ¼ 0.0004). For log10 D-dimer, in
addition to ART and HIV-RNA level, levels were greater
among older participants (0.062 higher with each 10 y; p ¼
0.002), for black participants (0.123; p ¼ 0.0009), for
participants with diabetes (0.161; p ¼ 0.01), and for those
with greater BMI (0.008 per unit higher; p ¼ 0.02). D-dimer
levels were lower for men ( 0.151; p ¼ 0.0003) and for those
with higher CD4þ cell counts ( 0.023 per 100 cells/mm
3
higher; p ¼ 0.002). To put these changes in perspective, the
IQRs on the log10 scale for IL-6 and D-dimer were 0.39 pg/ml
and 0.58 lg/ml, respectively. Differences as large as the IQR
for each marker were associated with 3- to 4-fold greater risks
of all-cause mortality.
Random Sample: Treatment Differences at 1 mo
Table 7 shows average changes in log10 transformed
biomarker levels 1 mo after randomization. IL-6 and D-
dimer increased signiﬁcantly (p ¼ 0.0005 and p , 0.0001,
respectively) from study entry to 1 mo in the DC group
compared to the VS group (p , 0.0001). Considering the non-
transformed levels, the median increase in D-dimer for DC
Table 4. Risk of Death Associated with Biomarker Levels at Study Entry for the Drug Conservation (DC) and Viral Suppression (VS)
Treatment Groups
Biomarker Type of Analysis DC VS p-Value for
Interaction
b
OR
a (95% CI) p-Value OR
a (95% CI) p-Value
hsCRP (lg/ml) Univariate 2.0 (1.2–3.4) 0.01 1.8 (0.7–4.6) 0.18 0.41
Adjusted
c 2.3 (1.2–4.4) 0.01 2.7 (0.9–7.9) 0.08 0.44
Amyloid A (mg/l) Univariate 1.6 (1.0–2.5) 0.06 1.2 (0.6–2.3) 0.67 0.08
Adjusted
c 1.6 (0.9–2.8) 0.11 1.5 (0.6–3.8) 0.40 0.11
Amyloid P (lg/ml) Univariate 0.7 (0.5–1.1) 0.14 0.8 (0.4–1.4) 0.43 0.22
Adjusted
c 0.8 (0.5–1.3) 0.40 0.7 (0.3–1.6) 0.46 0.31
IL-6 (pg/ml) Univariate 3.7 (2.1–6.4) ,0.0001 2.8 (1.3–6.1) 0.008 0.56
Adjusted
c 3.8 (2.1–7.2) 0.0002 2.4 (1.1–5.2) 0.03 0.33
D-dimer (lg/ml) Univariate 3.6 (1.7–7.3) 0.0005 2.6 (0.7–9.1) 0.14 0.38
Adjusted
c 5.9 (1.9–18.7) 0.002 7.1 (0.8–63.2) 0.08 0.30
F1.2 (pmol/l) Univariate 1.0 (0.6–1.6) 0.98 0.8 (0.3–2.2) 0.71 0.34
Adjusted
c 0.8 (0.4–1.5) 0.47 0.7 (0.2–2.2) 0.55 0.16
aOR derived from conditional logistic model, associated with a one IQR higher level of biomarker after log10 transformation (see last two columns of Table 3 for comparison of ORs for both
treatment groups combined).
bTreatment group 3 biomarker interaction (i.e., p-value for difference in ORs for DC and VS participants).
cAdjusted for age, hepatitis co-infection, prior CVD, smoking, and baseline CD4þcell count. Due to the small number of events adjustment was restricted to covariates measured at study
entry that were associated (p ¼ 0.10 or smaller) with mortality. For IL-6, one death and four controls were missing baseline data (see Figure 1). A separate adjusted model for VS
participants did not converge. Thus, for both DC and VS participants, unadjusted and adjusted ORs are estimated from a combined (DC and VS) model with an interaction term.
doi:10.1371/journal.pmed.0050203.t004
Table 5. Risk of Death Associated with Latest Level of Each
Biomarker
Biomarker OR
a 95% CI p-Value
hsCRP (lg/ml) 2.4 1.4–4.2 0.003
Amyloid A (mg/l) 1.4 1.0–1.9 0.09
Amyloid P (lg/ml) 0.7 0.4–1.0 0.04
IL-6 (pg/ml) 2.0 1.2–3.1 0.006
D-dimer (lg/ml) 2.2 1.1–4.1 0.02
F1.2 (pmol/l) 1.1 0.7–1.7 0.77
aOR associated with one IQR higher level of biomarker after log10 transformation (IQRs are
determined from random sample and shown in the footnote to Table 3). Each OR is
derived from a conditional logistic model (matching on age, sex, country, and date of
randomization)—adjusted for age, race (black versus other), use of ART and HIV-RNA level
(no ART versus ART and  400 versus ART and .400 copies/ml), CD4þcell count, smoking
status, BMI, prior CVD, diabetes, use of BP medication, use of lipid-lowering medication,
total/HDL cholesterol, co-infection with hepatitis B or C, and baseline level of log10
transformed biomarker. This model is equivalent to a model with change from baseline to
latest value as a covariate with the other covariates.
doi:10.1371/journal.pmed.0050203.t005
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0.60 pg/ml in the DC group (a 30% increase). For VS patients,
the median increases were 0.0 lg/ml and 0.12 pg/ml (a 5%
increase) for D-dimer and IL-6, respectively. Changes in
hsCRP and amyloid A were in the same direction—greater
increases for DC compared to VS patients—but did not differ
signiﬁcantly between treatment groups.
For both IL-6 and D-dimer, treatment differences were
greater for patients who were on ART at entry and had HIV-
RNA levels 400 copies/ml or below. For this subgroup (52% of
patients), D-dimer increased in the DC group by 0.07 lg/ml (a
27% increase) and declined in the VS group by 0.02 lg/ml (p
, 0.0001 for treatment difference). Similarly, for IL-6, the
median increases for DC and VS patients were 0.98 (a 43%
increase) and 0.08 pg/ml, respectively (p , 0.0001 for
difference).
The changes in IL-6 and D-dimer for the subgroup of DC
patients with HIV-RNA levels 400 copies/ml or below were
further examined according to HIV-RNA levels at 1 mo.
Following ART interruption, biomarker increases were greater
for those with higher HIV-RNA levels at 1 mo (Figures 3 and 4).
Results in Table 5 were used to estimate the potential impact
of treatment differences on mortality. For IL-6, the DC/VS
difference after 1 mo on the log10 scale was 0.08 pg/ml. Based
on the regression analysis cited in Table 5, a difference of this
magnitude is associated with a 16% increased risk of death
(95% CI, 10%–25%). Similarly, the 0.11 log10 higher level of D-
dimer for DC compared to VS participants is associated with a
24% (95% CI, 13%–46%) increased risk of death.
Impact of Adjustment for Latest Levels of IL-6 and D-
dimer on OR for DC Versus VS for All-Cause Mortality
Matched logistic models were used to assess the effect of
adjusting for latest levels of IL-6 and D-dimer on the DC/VS
OR for death. In the model with two controls per case, the
unadjusted OR for the DC versus the VS group was 1.3 (95%
CI, 0.8–2.2). Because this OR was considerably lower than the
hazard ratio previously reported for all-cause mortality [1],
we explored reasons for it and created an expanded case–
control data set. A chance imbalance in the number of DC
and VS participants selected as controls is the reason the OR
was lower. Among the 170 controls, 99 were in the DC group
and 71 were in the VS group. The expected number was 85 in
each group. With the expanded case–control study (four
controls for each death), the unadjusted DC/VS OR for all-
cause mortality was 1.8 (95% CI, 1.1–3.1). This estimate is
identical to that previously reported [1]. With adjustment for
latest level of IL-6, the OR was 1.5 (95% CI, 0.8–2.8); with
adjustment for latest level of D-dimer the OR was 1.4 (95%
CI, 0.8–2.5).
We also considered the effect of adjusting for both study
entry and latest levels of IL-6 and D-dimer and of adjusting
for HIV- RNA and CD4þ cell count on the DC/VS OR (Table
S5). Similar to an earlier report, adjustment for CD4þ cell
count had a greater effect on the OR (DC/VS) for mortality
(OR ¼ 1.2; 95% CI, 0.7–2.2) than adjustment for latest HIV-
RNA levels (OR ¼ 1.6; 95% CI, 0.9–2.9) [1]. With adjustment
for latest levels of IL-6, D-dimer, CD4þ cell count, and HIV-
RNA, the OR (DC/VS) was 1.3 (95% CI, 0.6–2.6).
Table 6. Characteristics of Random Sample of DC and VS Participants at Study Entry
Category Subcategory DC Group (n ¼ 249) VS Group (n ¼ 250) Total (n ¼ 499)
Demographics
a Age (25
th,7 5
th %ile) 44 44 44 (38,51)
Sex (% female) 28.9 29.6 29.3
Race (self-reported) White 35.7 37.6 36.7
Latino 52.6 48.4 50.5
Other 11.7 14.0 12.8
CD4þ (cells/mm
3) Nadir CD4þ (25
th,7 5
th %ile) 250 267 256 (146, 371)
Baseline (25
th,7 5
th %ile) 532 550 540 (432, 730)
Prior AIDS (%) 28.5 27.2 27.9
ART/HIV-RNA No ART (%) 26.9 24.8 25.9
ART and HIV-RNA  400 copies/ml (%) 53.8 50.8 52.3
ART and HIV-RNA .400 copies/ml (%) 19.3 24.4 21.8
Co-infection with hepatitis B/C (%) 24.1 19.2 21.6
Other risk factors Current smoker (%) 41.4 44.4 42.9
Diabetes (%) 8.8 9.6 9.2
Blood pressure lowering drugs (%) 24.1 30.4 27.3
Lipid lowering drugs (%) 16.5 18.0 17.2
Prior CVD (%) 0 0 0
Median total/HDL cholesterol (25
th,7 5
th %ile) 4.6 4.7 4.6 (3.5, 5.9)
BMI (kg/m
2) (25
th,7 5
th %ile) 26.8 26.7 26.7 (23.8, 30.5)
Biomarkers (25
th,7 5
th %ile) hsCRP (lg/ml) 2.56 2.07 2.30 (0.93, 4.73)
Amyloid A (mg/l) 3.30 3.61 3.40 (1.99, 6.34)
Amyloid P (lg/ml) 60.8 62.8 61.3 (49.0, 81.1)
IL-6 (pg/ml) 2.31 2.51 2.40 (1.57, 3.88)
D-dimer (lg/ml) 0.31 0.35 0.34 (0.17, 0.64)
F1.2 (pmol/l) 296.6 336.6 320.4 (225.0, 467.7)
aAll participants in the random sample were from the United States. Medians are cited for measured variables along with the 25th and 75th percentiles. The difference between the 75th
and 25th percentiles defines the IQR used to compute ORs in Tables 3, 4, and 5.
doi:10.1371/journal.pmed.0050203.t006
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Elevated levels of either IL-6 or D-dimer at study entry
were strongly related to all-cause mortality in the case–
control study. In the random sample, both D-dimer and IL-6
increased in the DC group compared to the VS group,
particularly in the large subgroup on ART at entry with a
suppressed HIV-RNA level. Increases in both markers in the
DC group were related to the level of HIV-RNA after 1 mo.
Finally, increases in these markers following randomization
were associated with mortality. Taken together, these ﬁndings
suggest that HIV-induced activation of inﬂammatory and
coagulation pathways has an adverse effect on all-cause
mortality among patients with relatively preserved CD4þ
counts, and that interrupting ART may further increase this
risk by raising IL-6 and D-dimer levels. Further research on
the relationship of these biomarkers with mortality and
morbidity in treated and untreated HIV-infected individuals
is warranted.
The associations between IL-6 and D-dimer levels at study
entry with all-cause mortality were much stronger than in
previous studies of non-HIV-infected populations that
usually focused on CVD morbidity and mortality [13,14,16–
18,20–22,31]. While these strong associations persisted in a
number of different analyses, including subgroups deﬁned by
hepatitis co-infection, baseline CD4þ cell count, and prior
disease history, the relatively small number of deaths
considered here compared to studies in the general pop-
ulation suggest that the results should be interpreted with
caution and require conﬁrmation. Findings for deaths
attributed to CVD or unwitnessed deaths were consistent
with those for all-cause mortality, although the number of
these deaths was small. The relationship of these biomarkers
with CVD morbidity and mortality will be the subject of a
separate report.
Patients in SMART were relatively healthy and did not have
advanced HIV disease. Deaths were attributed to a variety of
causes and were largely not due to AIDS, as would be
expected in a cohort of patients with CD4þ counts that
averaged about 600 cells/mm
3 at entry (Table S1) [32].
Associations of D-dimer and IL-6 with all-cause mortality
have been reported in other studies that included non-HIV-
infected participants [15,23,33].
Relationships between elevated IL-6 and D-dimer levels
and all-cause mortality were strong in both DC and VS
patients. However, our ﬁndings for patients on continuous
ART (VS group) require validation, as mortality rates were
low. However, if substantiated, and because most patients in
the VS group had HIV-RNA levels of 400 copies/ml or less at
Table 7. Biomarker, CD4þ Cell Count Change, and HIV-RNA Level Change 1 mo after Randomization
Biomarker DC Group, Mean (SD) or % VS Group, Mean (SD) or % Average Difference (SE)
a p-Value
a
hsCRP (lg/ml) (log10) 0.02 (0.41) 0.00 (0.41) 0.02 (0.03) 0.63
Amyloid A (mg/l) (log10) 0.03 (0.38) 0.01 (0.38) 0.00 (0.03) 0.88
Amyloid P (lg/ml) (log10)  0.02 (0.20) 0.01 (0.20)  0.03 (0.01) 0.05
IL-6 (pg/ml) (log10) 0.12 (0.30) 0.01 (0.34) 0.08 (0.02) 0.0005
D-dimer (lg/ml) (log10) 0.09 (0.31)  0.03 (0.31) 0.11 (0.02) ,0.0001
F1.2 (pmol/l) (log10)  0.04 (0.34)  0.03 (0.27)  0.02 (0.02) 0.44
CD4þ cell count (cells/mm
3)  104 (180) 18 (188)  130 (16) ,0.0001
Change in HIV-RNA (copies/ml) (log10) 1.17 (1.37)  0.31 (0.97) 1.46 (0.08) ,0.0001
HIV-RNA  400 copies/ml at 1 mo (%) 16.7 67.1  50.4 ,0.0001
aAdjusted for study entry level of the measurement of interest except for last row.
SD, standard deviation; SE standard error.
doi:10.1371/journal.pmed.0050203.t007
Figure 3. Change in Log10 IL-6 (pg/ml) from Baseline to 1 mo According
to HIV-RNA Level at 1 mo for Participants in the Drug Conservation (DC)
Group (CD4þ Guided Intermittent ART) with an HIV-RNA level 400
Copies/ml or Less at Baseline
doi:10.1371/journal.pmed.0050203.g003
Figure 4. Change in Log10 D-dimer (lg/ml) from Baseline to 1 mo
According to HIV-RNA Level at 1 mo for Participants in the Drug
Conservation (DC) Group (CD4þ Guided Intermittent ART) with an HIV-
RNA level 400 Copies/ml or less at Baseline
doi:10.1371/journal.pmed.0050203.g004
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even in the presence of effective ART, consistent with data
demonstrating ongoing viral replication, even in patients
with HIV-RNA of less than 50 copies/ml [34]. Considering our
ﬁnding that ART is associated with lower levels of these
biomarkers, more aggressive ART that might lower IL-6 and
D-dimer may warrant further investigation.
Increases in hsCRP, IL-6, and D-dimer from study entry to
the visit preceding the deathw e r ea s s o c i a t e dw i t ha n
increased risk of death. Whether the activation of tissue
factors secondary to inﬂammation is the key event is likely
but unproven in this study. Several alternative hypotheses are
possible. One study showed that tissue factor, an initiator of
coagulation, is generated by HIV-related proteins and could
have pathologic effects [35]. Another study found that HIV-
infected leukocytes transmigrate across the endothelium [36],
and this dissemination of virus could result in damage to
multiple organs. Alternatively, circulating lipopolysaccharide,
which has been shown to be higher in HIV-infected compared
to uninfected individuals [37], induces tissue factor tran-
scription, which in turn decreases F1.2 and soluble ﬁbrin,
resulting in ﬁbrin split products such as D-dimer [38].
Lipopolysaccharide also activates monocytes to produce
inﬂammatory cytokines, including IL-6 [39]. It is also possible
that elevations of inﬂammatory markers, such as hsCRP and
IL-6, and of D-dimer are independent events. In analyses that
considered the joint inﬂuence of IL-6 and D-dimer, each
remained strongly associated with all-cause mortality. Spe-
ciﬁc therapies that reduce the inﬂammatory response to HIV
and decrease hsCRP, IL-6, and D-dimer levels may warrant
investigation as an approach for reducing risk of death
among HIV-infected individuals [40–42].
ART interruption resulted in increases in IL-6 and D-
dimer, therefore the effect of these treatment differences on
the DC/VS OR for mortality was explored. Adjustment for
follow-up (latest) levels of IL-6 and D-dimer resulted in a
modest reduction of the DC/VS OR for mortality, supporting
the hypothesis that the excess risk of death in the ART
interruption group may be explained by biological mecha-
nisms for which IL-6 and D-dimer are markers.
There are some limitations in our work. Conﬁdence
intervals for ORs were wide due to the small number of
deaths. While we selected six biomarkers from a large number
of possible markers based on previous work in non-HIV-
infected populations, some associations may have resulted
from chance. This is less likely for the associations of IL-6 and
D-dimer levels at study entry with all-cause mortality, which
were highly signiﬁcant. Cost considerations limited the
number of controls for each death for which we could assess
biomarkers. This reduced the statistical power to detect
associations with mortality. The limited matching carried out,
particularly for the expanded case–control study with four
controls, may have resulted in incomplete control of
confounding factors. However, regression adjustment for a
number of covariates did not alter our overall conclusions.
We measured latest levels at the visit immediately prior to the
event of interest. For biomarker levels proximal to death, it is
possible that reverse causality (i.e., an already present disease
process caused the increase in the biomarker instead of vice
versa) may explain these ﬁndings. In addition, follow-up
specimens were not available for 11 deaths and 29 controls,
and this limited our ability to assess the prognostic
importance of biomarker changes on mortality. Finally, while
we did not ﬁnd evidence for different associations with
mortality for DC compared to VS patients, the number of
events experienced by VS patients was small, limiting the
power for those comparisons. Similarly, power for other
subgroup analyses considered was also low.
In summary, elevated levels of D-dimer and IL-6 identify
HIV-infected patients at high risk of death. The magnitude of
the association is clinically relevant and reasons for it require
further study.
Supporting Information
Figure S1. SMART Study Design and Flow Diagram for Case–Control
Study with 1:4 Matching for Deaths and Controls
Matching was on date of randomization to ensure latest levels for
deaths, and controls were determined at similar time point following
randomizations.
doi:10.1371/journal.pmed.0050203.sg001
Figure S2. Baseline Level of hsCRP (lg/ml) for Each of 85 Death–
Control Triads Ordered by hsCRP Level of Deaths Plotted on
Logarithmic Scale (Log10)
Solid lines give median levels at baseline for deaths (4.3 lg/ml) and
controls (2.1 lg/ml). Red circles and lines are for deaths, and blue
circles and lines are for controls.
doi:10.1371/journal.pmed.0050203.sg002
Figure S3. Baseline Level of Amyloid A (mg/l) for Each of 85 Death–
Control Triads Ordered by Amyloid A Level of Deaths Plotted on
Logarithmic Scale (Log10)
Solid lines give median levels at baseline for deaths (4.75 mg/l) and
controls (3.65 mg/l). Red circles and lines are for deaths, and blue
circles and lines are for controls.
doi:10.1371/journal.pmed.0050203.sg003
Figure S4. Baseline Level of Amyloid P (lg/l) for Each of 85 Death–
Control Triads Ordered by Amyloid P Level of Deaths Plotted on
Logarithmic Scale (Log10)
Solid lines give median levels at baseline for deaths (58.8 lg/l) and
controls (67.8 lg/l). Red circles and lines are for deaths, and blue
circles and lines are for controls.
doi:10.1371/journal.pmed.0050203.sg004
Figure S5. Baseline Level of IL-6 (pg/ml) for Each of 84 Death–
Control Triads Ordered by IL-6 Level of Deaths Plotted on
Logarithmic Scale (log10)
IL-6 level was missing for one death. Solid lines give median levels at
baseline for deaths (3.8 pg/ml) and controls (2.3 pg/ml). Red circles
and lines are for deaths, and blue circles and lines are for controls.
doi:10.1371/journal.pmed.0050203.sg005
Figure S6. Baseline Level of D-dimer (lg/ml) for Each of 85 Death–
Control Triads Ordered by D-dimer Level of Deaths Plotted on
Logarithmic Scale (log10)
Solid lines give median levels at baseline for deaths (0.49 lg/ml) and
controls (0.26 lg/ml). Red circles and lines are for deaths, and blue
circles and lines are for controls.
doi:10.1371/journal.pmed.0050203.sg006
Figure S7. Baseline Level of F1.2 (pmol/l) for Each of 84 Death–
Control Triads Ordered by F1.2 Level of Deaths Plotted on
Logarithmic Scale (Log10)
F1.2 level was missing for one death. Solid lines give median levels at
baseline for deaths (344.0 pmol/l) and controls (351.4 pmol/l). Red
circles and lines are for deaths, and blue circles and lines are for
controls.
doi:10.1371/journal.pmed.0050203.sg007
Table S1. Underlying Cause of Death for Participants in SMART
doi:10.1371/journal.pmed.0050203.st001
Table S2. Odds Ratio Associated with a One IQR Higher Level of
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doi:10.1371/journal.pmed.0050203.st002
Table S3. Risk of Death Associated with Biomarker Levels at
Baseline—Four Controls Per Death
doi:10.1371/journal.pmed.0050203.st003
Table S4. Study Entry and Latest Levels of Six Biomarkers for Deaths
and Matched Controls (Four Matched Controls for Each Death)
doi:10.1371/journal.pmed.0050203.st004
Table S5. Estimates of the Odds Ratio for DC Versus VS Participants
for All-Cause Mortality After Adjustment for Study Entry and Latest
Levels of IL-6, D-dimer, CD4þ Cell Count, and HIV RNA Level
doi:10.1371/journal.pmed.0050203.st005
Text S1. CONSORT Checklist
doi:10.1371/journal.pmed.0050203.sd001
Text S2. Protocol
doi:10.1371/journal.pmed.0050203.sd002
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Editors’ Summary
Background. Globally, more than 30 million people are infected with the
human immunodeficiency virus (HIV), the virus that causes acquired
immunodeficiency syndrome (AIDS). HIV infects and destroys immune
system cells (including CD4 cells, a type of lymphocyte). The first stage of
HIV infection can involve a short flu-like illness but in the second stage,
which can last many years, HIV replicates in the lymph glands (small
immune system organs throughout the body) without causing any
symptoms. Eventually, however, the immune system becomes so
damaged that HIV-infected individuals begin to succumb to ‘‘opportun-
istic’’ infections (for example, bacterial pneumonia) and cancers (in
particular, Karposi sarcoma) that the immune system would normally
prevent. AIDS itself is characterized by one or more severe opportunistic
infections or cancers (so-called AIDS-related diseases) and by a low blood
CD4 cell count. HIV infections cannot be cured but antiretroviral therapy
(ART)—combinations of powerful antiretroviral drugs—can keep them in
check, so many HIV-positive people now have substantially improved life
expectancy.
Why Was This Study Done? Unfortunately, the effectiveness of ART
sometimes wanes over time and prolonged ART can cause unpleasant
side effects. Consequently, alternative ART regimens are continually
being tested in clinical trials. In the Strategies for Management of Anti-
Retroviral Therapy (SMART) trial, for example, HIV-positive patients
received either continuous ART (the viral suppression or VS arm), or ART
only when their CD4 cell counts were below 250 cells/mm
3 (the drug
conservation or DC arm; the normal adult CD4 cell count is about 1,000
cells/mm
3). Unexpectedly, more people died in the DC arm than in the
VS arm from non-AIDS diseases (including heart and circulation
problems), a result that led to the trial being stopped early. One
possible explanation for these excess deaths is that increased HIV levels
following ART interruption might have induced an inflammatory
response (a non-specific immune response that occurs with infection
or wounding) and/or a hypercoagulable state (a condition in which
blood clots form inside undamaged blood vessels) and that these
changes increased the risk of death from non-AIDS diseases. In this
study, the researchers test this hypothesis.
What Did the Researchers Do and Find? The researchers measured the
levels of proteins that indicate the presence of inflammation or increased
coagulation (biomarkers) in stored blood samples from the 85 people
who died during the SMART trial (55 and 30 of the participants assigned
to receive DC and VS, respectively) and from 170 survivors who served as
comparison (control) participants. (Two control participants were
‘‘matched’’ to each participant who had died (cases). In this ‘‘case-
control’’ study, an increased risk of death was associated with higher
levels at study entry of the inflammation biomarkers high-sensitivity C-
reactive protein (hsCRP) and interleukin 6 (IL-6) and of the coagulation
biomarker D-dimer. The risk of death among people with hsCRP values in
the highest quarter of measured values was twice that among people
with hsCRP values in the lowest quarter (this is expressed as an odds
ratio of 2). For IL-6 and D-dimer, the equivalent odds ratios were 8.3 and
12.4, respectively. Furthermore, increases in hsCRP, IL-6 and D-dimer
after study entry were associated with an increased risk of death. The
researchers also measured blood levels of the same biomarkers in 250
randomly chosen patients from each of the two treatment arms. IL-6
levels increased by 30% over the first month of the trial in the DC arm
but were unchanged in the VS arm. Over the same period, D-dimer levels
increased by 16% and 5% in the DC and VS arms, respectively. Increases
in both markers in the DC arm were related to HIV RNA levels after one
month.
What Do These Findings Mean? Taken together, these findings suggest
that HIV-induced activation of inflammation and coagulation increases
the risk of death among HIV-positive patients and that interrupting ART
further increases this risk, possibly by increasing IL-6 and D-dimer levels.
Because only a small number of people died in this study, the
relationship between these biomarkers and death and illness among
treated and untreated HIV-positive individuals needs to be confirmed in
further studies. However, these findings suggest that the development
of therapies that reduce the effect that HIV replication has on
inflammation and blood coagulation, or that reduce IL-6 and D-dimer
levels, might extend the life-expectancy of HIV-positive people.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050203.
  Information is available from the US National Institute of Allergy and
Infectious Diseases on HIV infection and AIDS and about the SMART
trial
  HIV InSite has comprehensive information on all aspects of HIV/AIDS
  Information is also available from Avert, an international AIDS charity,
on HIV/AIDS
  More information about the SMART trial is available on ClinicalTrials.
gov, a database of clinical trials maintained by the US National
Institutes of Health
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